Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

--No pruritus observed during 14-day treatment of the once-daily human therapeutic dose of 15 mg. --FXR target engagement biomarker FGF19 increased 1632% on Day 14 of treatment with 15 mg, once-daily. ...

Full "IntellAsia: Resources" article